Loading...

Alligator Bioscience

DB:7AL
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7AL
DB
SEK2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
7AL Share Price and Events
7 Day Returns
-2.7%
DB:7AL
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-8.2%
DB:7AL
-5.6%
DE Biotechs
-4.5%
DE Market
7AL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alligator Bioscience (7AL) -2.7% 9.5% 13.5% -8.2% - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 7AL underperformed the Biotechs industry which returned -5.6% over the past year.
  • 7AL underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
7AL
Industry
5yr Volatility vs Market

7AL Value

 Is Alligator Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alligator Bioscience. This is due to cash flow or dividend data being unavailable. The share price is €2.355.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alligator Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alligator Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7AL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK-2.13
OM:ATORX Share Price ** OM (2019-04-25) in SEK SEK25.1
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alligator Bioscience.

DB:7AL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ATORX Share Price ÷ EPS (both in SEK)

= 25.1 ÷ -2.13

-11.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alligator Bioscience is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alligator Bioscience is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alligator Bioscience's expected growth come at a high price?
Raw Data
DB:7AL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
39%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alligator Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alligator Bioscience's assets?
Raw Data
DB:7AL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK5.94
OM:ATORX Share Price * OM (2019-04-25) in SEK SEK25.1
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:7AL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ATORX Share Price ÷ Book Value per Share (both in SEK)

= 25.1 ÷ 5.94

4.23x

* Primary Listing of Alligator Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alligator Bioscience is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alligator Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alligator Bioscience has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7AL Future Performance

 How is Alligator Bioscience expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alligator Bioscience expected to grow at an attractive rate?
  • Alligator Bioscience's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Alligator Bioscience's earnings growth is expected to exceed the Germany market average.
  • Alligator Bioscience's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:7AL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7AL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 39%
DB:7AL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 55.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7AL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 weeks ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7AL Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 149 -134 1
2021-12-31 236 -78 36 2
2020-12-31 205 -23 24 3
2019-12-31 0 -159 -186 3
DB:7AL Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 26 -141 -152
2018-12-31 27 -104 -150
2018-09-30 53 -97 -107
2018-06-30 54 -80 -93
2018-03-31 55 -71 -86
2017-12-31 57 -100 -64
2017-09-30 12 -80 -96
2017-06-30 15 -76 -77
2017-03-31 18 -41 -91
2016-12-31 59 -38 -48
2016-09-30 55 -52 -68

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alligator Bioscience's earnings are expected to grow significantly at over 20% yearly.
  • Alligator Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7AL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 weeks ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Alligator Bioscience Company Filings, last reported 3 weeks ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7AL Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 0.53 0.95 0.10 2.00
2020-12-31 0.34 0.44 0.24 2.00
2019-12-31 -2.60 -2.59 -2.61 2.00
DB:7AL Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 -2.13
2018-12-31 -2.10
2018-09-30 -1.50
2018-06-30 -1.30
2018-03-31 -1.21
2017-12-31 -0.89
2017-09-30 -1.38
2017-06-30 -1.17
2017-03-31 -1.45
2016-12-31 -0.80
2016-09-30 -1.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Alligator Bioscience is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Alligator Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alligator Bioscience has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7AL Past Performance

  How has Alligator Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alligator Bioscience's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alligator Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alligator Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alligator Bioscience's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alligator Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alligator Bioscience Company Filings, last reported 3 weeks ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7AL Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 26.29 -152.22 61.56
2018-12-31 27.03 -150.04 58.76
2018-09-30 52.66 -106.94 54.09
2018-06-30 54.24 -93.08 51.50
2018-03-31 55.13 -86.47 47.57
2017-12-31 56.88 -63.76 43.75
2017-09-30 11.82 -95.62 40.15
2017-06-30 15.14 -77.40 37.47
2017-03-31 17.65 -91.46 34.55
2016-12-31 58.72 -48.36 32.77
2016-09-30 54.81 -68.46 31.12
2015-12-31 291.62 207.38 32.48
2014-12-31 1.23 -76.78 31.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alligator Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alligator Bioscience has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alligator Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alligator Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alligator Bioscience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7AL Health

 How is Alligator Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alligator Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alligator Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alligator Bioscience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alligator Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alligator Bioscience Company Filings, last reported 3 weeks ago.

DB:7AL Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 424.04 20.67 349.69
2018-12-31 468.31 0.00 383.13
2018-09-30 498.78 0.00 414.88
2018-06-30 538.30 0.00 444.58
2018-03-31 575.92 0.00 474.68
2017-12-31 617.96 0.00 472.92
2017-09-30 605.40 0.00 513.22
2017-06-30 631.12 0.00 540.52
2017-03-31 662.06 0.00 639.74
2016-12-31 676.19 0.00 659.14
2016-09-30 370.85 0.00 346.46
2015-12-31 396.97 0.00 365.61
2014-12-31 68.52 0.00 37.43
  • Alligator Bioscience's level of debt (4.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Alligator Bioscience's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alligator Bioscience has sufficient cash runway for 2.4 years based on current free cash flow.
  • Alligator Bioscience has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 39.5% each year.
X
Financial health checks
We assess Alligator Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alligator Bioscience has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7AL Dividends

 What is Alligator Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alligator Bioscience dividends. Estimated to be 0% next year.
If you bought €2,000 of Alligator Bioscience shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alligator Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alligator Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7AL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7AL Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alligator Bioscience has not reported any payouts.
  • Unable to verify if Alligator Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alligator Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alligator Bioscience has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Alligator Bioscience's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Alligator Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alligator Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alligator Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7AL Management

 What is the CEO of Alligator Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Per Norlén
COMPENSATION SEK2,599,000
AGE 48
TENURE AS CEO 4.3 years
CEO Bio

Dr. Per Norlén has been the Chief Executive Officer at Alligator Bioscience AB (publ) since 2015 and served as its Chief Medical Officer from 2010 to January 2018 and was its Vice President of Development. Dr. Norlén has 10 years of drug development experience, from medic at phase I clinical pharmacology units, to design and interpretation within the pharmaceutical industry. Before joining Alligator Bioscience, Dr. Norlén was employed at AstraZeneca R&D for 4 years, as Senior Clinical Pharmacology Physician and Global Discipline Leader of Clinical Pharmacology Physicians, with responsibility for phase I/II clinical trials within respiratory and inflammation. Dr. Norlén is M.D., PhD, board certified specialist in Clinical Pharmacology and Associate Professor in Experimental.

CEO Compensation
  • Per's compensation has increased whilst company is loss making.
  • Per's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alligator Bioscience management team in years:

3.8
Average Tenure
54
Average Age
  • The tenure for the Alligator Bioscience management team is about average.
Management Team

Per Norlén

TITLE
Chief Executive Officer
COMPENSATION
SEK3M
AGE
48
TENURE
4.3 yrs

Per-Olof Schrewelius

TITLE
Chief Financial Officer
AGE
55
TENURE
3.3 yrs

Cecilia Hofvander

TITLE
Director of Investor Relations & Communications
AGE
51

Christina Furebring

TITLE
Senior Vice President of Preclinical Development
AGE
54
TENURE
18.3 yrs

Charlotte Russell

TITLE
Chief Medical Officer
AGE
54
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Alligator Bioscience board of directors in years:

4.3
Average Tenure
62
Average Age
  • The tenure for the Alligator Bioscience board of directors is about average.
Board of Directors

Peter Benson

TITLE
Chairman
COMPENSATION
SEK500K
AGE
63
TENURE
5.3 yrs

Ulrika Danielsson

TITLE
Independent Director
COMPENSATION
SEK392K
AGE
46
TENURE
3.3 yrs

Anders Ekblom

TITLE
Director
COMPENSATION
SEK295K
AGE
64
TENURE
1.9 yrs

Carl Arne Borrebaeck

TITLE
Non-Independent Director
COMPENSATION
SEK275K
AGE
70
TENURE
18.3 yrs

Kenth Petersson

TITLE
Independent Director
COMPENSATION
SEK303K
AGE
62
TENURE
18.3 yrs

Jonas Sjögren

TITLE
Independent Director
COMPENSATION
SEK303K
AGE
52
TENURE
4.3 yrs

Laura von Schantz

TITLE
Director
AGE
36
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alligator Bioscience insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Feb 19 Buy Anders Ekblom Individual 21. Feb 19 21. Feb 19 1,400 €2.16 €3,030
29. Dec 18 Buy Per Norlén Individual 28. Dec 18 28. Dec 18 10,000 €2.15 €21,470
X
Management checks
We assess Alligator Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alligator Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7AL News

Simply Wall St News

7AL Company Info

Description

Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. The company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific fusion format for the development of novel dual-action antibodies. It develops ADC-1013, which is a human, monospecific, agonistic, and IgG1 antibody intended for immunotherapy of metastatic cancer; ATOR-1015, a bispecific immune activating antibody for tumor-directed immunotherapy; and ATOR-1017, an agonistic IgG4 antibody for tumor-directed immunotherapy. The company is also developing ALG.APV-527, a bispecific agonistic antibody for tumor-directed immunotherapy. It has a strategic partnership with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527, a novel immunotherapy bispecific antibody candidate; and collaborations with Stanford and Navarra universities. Alligator Bioscience AB (publ) has operations in the United States, Sweden, and internationally. The company was founded in 2001 and is headquartered in Lund, Sweden.

Details
Name: Alligator Bioscience AB (publ)
7AL
Exchange: DB
Founded: 2001
SEK168,786,923
71,388,615
Website: http://www.alligatorbioscience.se
Address: Alligator Bioscience AB (publ)
Medicon Village,
Scheelevagen 2,
Lund,
Skåne County, 223 81,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ATORX Share Capital OMX Nordic Exchange Stockholm SE SEK 23. Nov 2016
DB 7AL Share Capital Deutsche Boerse AG DE EUR 23. Nov 2016
LSE 0RK9 Share Capital London Stock Exchange GB SEK 23. Nov 2016
BATS-CHIXE ATORXS Share Capital BATS 'Chi-X Europe' GB SEK 23. Nov 2016
Number of employees
Current staff
Staff numbers
56
Alligator Bioscience employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:50
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/04/17
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.